Claims for Patent: 9,486,450

Summary for Patent: 9,486,450

Title:	Hydroxybupropion and related compounds as modulators of drug plasma levels
Abstract:	This disclosure relates to methods administering hydroxybupropion or a prodrug thereof in conjunction with dextromethorphan to a human being. Dosage forms, drug delivery systems, and methods related to dextromethorphan or dextrorphan and hydroxybupropion or a prodrug of hydroxybupropion are also disclosed.
Inventor(s):	Herriot Tabuteau
Assignee:	Antecip Bioventures II LLC
Application Number:	US14/617,624
Patent Claims:	1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering a) a hydroxybupropion or a bupropion with b) a dextromethorphan at least daily to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the hydroxybupropion or the bupropion and the dextromethorphan are the sole active agents administered to the human being, wherein the hydroxybupropion or the bupropion is administered in an amount that results in an AUC0-12 of the dextromethorphan that is at least about 40 ng·hr/mL, and wherein, on the eighth day that the hydroxybupropion or the bupropion and the dextromethorphan are co-administered, the AUC0-12 of the dextromethorphan is at least about 20 times the AUC0-12 of the dextromethorphan that would result from administering the same amount of the dextromethorphan without the hydroxybupropion or the bupropion. 2. The method of claim 1, wherein the AUC0-12 of the dextromethorphan on the eighth day is at least about 50 ng·hr/mL. 3. The method of claim 1, wherein the AUC0-12 of the dextromethorphan on the eighth day is at least about 100 ng·hr/mL. 4. The method of claim 1, wherein the AUC0-12 of the dextromethorphan on the eighth day is at least about 400 ng·hr/mL. 5. The method of claim 1, wherein the AUC0-12 of the dextromethorphan on the eighth day is at least about 700 ng·hr/mL. 6. The method of claim 1, wherein the AUC0-24 of the dextromethorphan on the eighth day is at least about 100 ng·hr/mL. 7. The method of claim 1, wherein the AUC0-24 of the dextromethorphan on the eighth day is at least about 1000 ng·hr/mL. 8. The method of claim 1, wherein the AUC0-inf of the dextromethorphan on the eighth day is at least about 2000 ng·hr/mL. 9. The method of claim 1, wherein the AUC0-inf of the dextromethorphan on the eighth day is at least about 3000 ng·hr/mL. 10. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering a) a hydroxybupropion or a bupropion with b) a dextromethorphan to the human being, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the hydroxybupropion or the bupropion and the dextromethorphan are the sole active agents administered to the human being, wherein the hydroxybupropion or the bupropion is administered at least daily for at least eight consecutive days in an amount that results in a Cmax of the dextromethorphan that is at least about 6 ng/mL, and wherein, on the eighth day that the hydroxybupropion or the bupropion and the dextromethorphan are co-administered, the AUC0-12 of the dextromethorphan is at least about 20 times the AUC0-12 of the dextromethorphan that would result from administering the same amount of the dextromethorphan without the hydroxybupropion or the bupropion. 11. The method of claim 10, wherein the Cmax of the dextromethorphan on the eighth day is at least about 10 ng/mL. 12. The method of claim 10, wherein the Cmax of the dextromethorphan on the eighth day is at least about 60 ng/mL. 13. The method of claim 10, wherein the Cmax of the dextromethorphan on the eighth day is at least about 80 ng/mL. 14. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering at least daily for at least eight consecutive days a) a hydroxybupropion or a bupropion with b) a dextromethorphan to the human being, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein the hydroxybupropion or the bupropion and the dextromethorphan are the sole active agents administered to the human being, wherein the hydroxybupropion or the bupropion is administered in an amount that results in a Cavg of the dextromethorphan, over the period between two separate and consecutive administrations of the dextromethorphan, that is at least about 5 ng/mL, and wherein, on the eighth day that the hydroxybupropion or the bupropion and the dextromethorphan are co-administered, the AUC0-12 of the dextromethorphan is at least about 20 times the AUC0-12 of the dextromethorphan that would result from administering the same amount of the dextromethorphan without the hydroxybupropion or the bupropion. 15. The method of claim 14, wherein the hydroxybupropion or the bupropion is administered in an amount that results in a Cavg of the dextromethorphan, over the period between two separate and consecutive administrations of the dextromethorphan, that is at least about 60 ng/mL. 16. The method of claim 14, wherein the Cavg of the dextromethorphan on the eighth day is at least about 8 ng/mL, wherein the Cavg is for the period between two separate and consecutive administrations of the dextromethorphan, or if the dextromethorphan is administered only once on the eighth day, the Cavg is for the period of twelve hours from the only dose of the dextromethorphan on the eighth day. 17. The method of claim 14, wherein the Cavg of the dextromethorphan on the eighth day is at least about 30 ng/mL, wherein the Cavg is for the period between two separate and consecutive administrations of the dextromethorphan, or if the dextromethorphan is administered only once on the eighth day, the Cavg is for the period of twelve hours from the only dose of the dextromethorphan on the eighth day. 18. The method of claim 1, wherein the human being is at risk of experiencing an adverse event as a result of being treated with the bupropion and the risk of the human being experiencing an adverse event is reduced by the co-administration of the dextromethorphan. 19. The method of claim 1, wherein the hydroxybupropion or the bupropion and the dextromethorphan are co-administered for at least thirty days. 20. The method of claim 1, wherein the hydroxybupropion or the bupropion and the dextromethorphan are independently administered either orally or parenterally. 21. The method of claim 20, wherein the hydroxybupropion or the bupropion is orally administered in a solid dosage form. 22. The method of claim 20, wherein the dextromethorphan is orally administered in a solid dosage form. 23. The method of claim 10, wherein the hydroxybupropion or the bupropion and the dextromethorphan are independently administered either orally or parenterally. 24. The method of claim 23, wherein the hydroxybupropion or the bupropion is orally administered in a solid dosage form. 25. The method of claim 23, wherein the dextromethorphan is orally administered in a solid dosage form. 26. The method of claim 14, wherein the hydroxybupropion or the bupropion and the dextromethorphan are independently administered either orally or parenterally. 27. The method of claim 26, wherein the hydroxybupropion or the bupropion is orally administered in a solid dosage form. 28. The method of claim 26, wherein the dextromethorphan is orally administered in a solid dosage form. 29. The method of claim 14, wherein the plasma level of hydroxybupropion is about 0.1 μM to about 10 μM. 30. The method of claim 14, wherein the hydroxybupropion or the bupropion and the dextromethorphan are co-administered in a single dosage form.